Research and Markets: Male Hypogonadism – Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/3sqllb/male_hypogonadism) has announced the addition of Global Markets Direct's new report "Male Hypogonadism - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Male Hypogonadism - Pipeline Review, H2 2012', provides an overview of the Male Hypogonadism therapeutic pipeline. This report provides information on the therapeutic development for Male Hypogonadism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Hypogonadism. 'Male Hypogonadism - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Male Hypogonadism.

- A review of the Male Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Male Hypogonadism pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

Read more:
Research and Markets: Male Hypogonadism - Pipeline Review, H2 2012

Word Count: 249